Neoadjuvant target therapy with ensartinib in lung adenocarcinoma with EML4-ALK fusion variant: a case report and literature review

被引:1
作者
Wu, Yimin [1 ]
Huang, Lijian [1 ]
Li, Wenshan [1 ]
Chai, Ying [1 ,2 ]
机构
[1] Zhejiang Univ, Affiliated Hosp 2, Coll Med, Dept Thorac Surg, Hangzhou, Peoples R China
[2] Zhejiang Univ, Affiliated Hosp 2, Coll Med, Dept Thorac Surg, 88 Jiefang Rd, Hangzhou 310009, Peoples R China
关键词
anaplastic lymphoma kinase rearrangement; neoadjuvant target therapy; non-small-cell lung cancer; OPEN-LABEL; ALK; CHEMOTHERAPY; ALECTINIB; SAFETY; NSCLC;
D O I
10.1097/CAD.0000000000001432
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Although neoadjuvant target therapy has been used to treat patients with non-small-cell lung cancer (NSCLC), most of these patients have mutations in the epidermal growth factor receptor (EGFR) gene. Few patients to date have received neoadjuvant target therapy for NSCLC containing variants in genes encoding anaplastic lymphoma kinase-tyrosine kinase inhibitors (ALK-TKIs). Herein, we present a 51-year-old man with a lung mass in the left lower lobe with enlarged mediastinal lymph nodes. He was diagnosed with NSCLC after needle lung biopsy, with next-generation sequencing showing an echinoderm microtubule-associated protein-like 4 gene-anaplastic lymphoma kinase (EML4-ALK) fusion variant. The patient received neoadjuvant ensartinib, a second-generation ALK-TKI, for 5 months, followed by successful lobectomy through uniportal video-assisted thoracic surgery and adjuvant ensartinib. To our knowledge, few patients with ALK-positive NSCLC had received neoadjuvant treatment with ensartinib. Findings in this patient may widen indications for neoadjuvant target therapy in the treatment of resectable stage II-IIIA ALK-positive NSCLC.
引用
收藏
页码:699 / 706
页数:8
相关论文
共 16 条
[1]   Feasibility and Safety of Neoadjuvant Alectinib in Pulmonary Invasive Mucinous Adenocarcinoma with ALK Rearrangement: Case Report and Literature Review [J].
Gu, Rumeng ;
Shi, Ziling ;
Duan, Ting ;
Song, Meijun .
ONCOTARGETS AND THERAPY, 2021, 14 :5107-5113
[2]   Ensartinib vs Crizotinib for Patients With Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer A Randomized Clinical Trial [J].
Horn, Leora ;
Wang, Ziping ;
Wu, Gang ;
Poddubskaya, Elena ;
Mok, Tony ;
Reck, Martin ;
Wakelee, Heather ;
Chiappori, Alberto A. ;
Lee, Dae Ho ;
Breder, Valeriy ;
Orlov, Sergey ;
Cicin, Irfan ;
Cheng, Ying ;
Liu, Yunpeng ;
Fan, Yun ;
Whisenant, Jennifer G. ;
Zhou, Yi ;
Oertel, Vance ;
Harrow, Kim ;
Liang, Chris ;
Mao, Li ;
Selvaggi, Giovanni ;
Wu, Yi-Long .
JAMA ONCOLOGY, 2021, 7 (11) :1617-1625
[3]   Phase II, Open-label, Single-arm, Multicenter Study to Assess the Activity and Safety of Alectinib as Neoadjuvant Treatment in Surgically Resectable Stage III ALK-positive NSCLC: ALNEO Trial [J].
Leonetti, Alessandro ;
Minari, Roberta ;
Boni, Luca ;
Gnetti, Letizia ;
Verze, Michela ;
Ventura, Luigi ;
Musini, Luca ;
Tognetto, Michele ;
Tiseo, Marcello .
CLINICAL LUNG CANCER, 2021, 22 (05) :473-477
[4]   Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry [J].
Mazieres, J. ;
Drilon, A. ;
Lusque, A. ;
Mhanna, L. ;
Cortot, A. B. ;
Mezquita, L. ;
Thai, A. A. ;
Mascaux, C. ;
Couraud, S. ;
Veillon, R. ;
Van Den Heuvel, M. ;
Neal, J. ;
Peled, N. ;
Fruh, M. ;
Ng, T. L. ;
Gounant, V ;
Popat, S. ;
Diebold, J. ;
Sabari, J. ;
Zhu, V. W. ;
Rothschild, S. I. ;
Bironzo, P. ;
Martinez-Marti, A. ;
Curioni-Fontecedro, A. ;
Rosell, R. ;
Lattuca-Truc, M. ;
Wiesweg, M. ;
Besse, B. ;
Solomon, B. ;
Barlesi, F. ;
Schouten, R. D. ;
Wakelee, H. ;
Camidge, D. R. ;
Zalcman, G. ;
Novello, S. ;
Ou, S. I. ;
Milia, J. ;
Gautschi, O. .
ANNALS OF ONCOLOGY, 2019, 30 (08) :1321-1328
[5]   Alectinib versus chemotherapy in crizotinib-pretreated anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer: results from the phase III ALUR study [J].
Novello, S. ;
Mazieres, J. ;
Oh, I-J. ;
de Castro, J. ;
Migliorino, M. R. ;
Helland, A. ;
Dziadziuszko, R. ;
Griesinger, F. ;
Kotb, A. ;
Zeaiter, A. ;
Cardona, A. ;
Balas, B. ;
Johannsdottir, H. K. ;
Das-Gupta, A. ;
Wolf, J. .
ANNALS OF ONCOLOGY, 2018, 29 (06) :1409-1416
[6]   Tumor Resistance against ALK Targeted Therapy-Where It Comes From and Where It Goes [J].
Sharma, Geeta Geeta ;
Mota, Ines ;
Mologni, Luca ;
Patrucco, Enrico ;
Gambacorti-Passerini, Carlo ;
Chiarle, Roberto .
CANCERS, 2018, 10 (03)
[7]  
Solomon BJ, 2014, NEW ENGL J MED, V371, P2167, DOI [10.1056/NEJMoa1408440, 10.1056/NEJMx150034]
[8]   First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study [J].
Soria, Jean-Charles ;
Tan, Daniel S. W. ;
Chiari, Rita ;
Wu, Yi-Long ;
Paz-Ares, Luis ;
Wolf, Juergen ;
Geater, Sarayut L. ;
Orlov, Sergey ;
Cortinovis, Diego ;
Yu, Chong-Jen ;
Hochmair, Maximillian ;
Cortot, Alexis B. ;
Tsai, Chun-Ming ;
Moro-Sibilot, Denis ;
Campelo, Rosario G. ;
McCulloch, Tracey ;
Sen, Paramita ;
Dugan, Margaret ;
Pantano, Serafino ;
Branle, Fabrice ;
Massacesi, Cristian ;
de Castro, Gilberto, Jr. .
LANCET, 2017, 389 (10072) :917-929
[9]   Rational combination therapy with PARP and MEK inhibitors capitalizes on therapeutic liabilities in RAS mutant cancers [J].
Sun, Chaoyang ;
Fang, Yong ;
Yin, Jun ;
Chen, Jian ;
Ju, Zhenlin ;
Zhang, Dong ;
Chen, Xiaohua ;
Vellano, Christopher P. ;
Jeong, Kang Jin ;
Ng, Patrick Kwok-Shing ;
Eterovic, Agda Karina B. ;
Bhola, Neil H. ;
Lu, Yiling ;
Westin, Shannon N. ;
Grandis, Jennifer R. ;
Lin, Shiaw-Yih ;
Scott, Kenneth L. ;
Peng, Guang ;
Brugge, Joan ;
Mills, Gordon B. .
SCIENCE TRANSLATIONAL MEDICINE, 2017, 9 (392)
[10]   Neoadjuvant Gefitinib in Resectable Early Stage EGFR Mutant Non-Small Cell Lung Cancer (NSCLC): A Window-of-Opportunity Study [J].
Tan, A. ;
Chua, K. P. ;
Takano, A. ;
Alvarez, J. ;
Ong, B. H. ;
Koh, T. ;
Aung, Z. W. ;
Jain, A. ;
Lai, G. ;
Tan, W. L. ;
Ang, M. K. ;
Ng, Q. S. ;
Kanesvaran, R. ;
Rajasekaran, T. ;
Iyer, N. G. ;
Lim, W. T. ;
Zhai, W. ;
Toh, C. K. ;
Skanderup, A. ;
Tan, E. H. ;
Tan, D. .
JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) :S609-S610